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Summary
Hypertrophic cardiomyopathy (HCM) is an autosomal
dominantly inherited disease of the cardiac sarcomere,
caused by numerous mutations in genes encoding pro-
tein components of this structure. Mutation carriers are
at risk of sudden cardiac death, mostly as adolescents
or young adults. The reproductive disadvantage incurred
may explain both the global occurrence of diverse in-
dependent HCM-associated mutations and the rare re-
ports of founder effects within populations. We have
investigated whether this holds true for two South Af-
rican subpopulations, one of mixed ancestry and one of
northern-European descent. Previously, we had detected
three novel mutations—Ala797Thr in the b-myosin
heavy-chain gene (bMHC), Arg92Trp in the cardiac tro-
ponin T gene (cTnT), and Arg645His in the myosin-
binding protein C gene (MyBPC)—and two documented
bMHC mutations (Arg403Trp and Arg249Gln). Here
we report three additional novel mutations—Gln499Lys
in bMHC and Val896Met and Dc756 in MyBPC—and
the documented bMHC Arg719Gln mutation. Seven of
the nine HCM-causing mutations arose independently;
no conclusions can be drawn for the remaining two.
However, the bMHC Arg403Trp and Ala797Thr and
cTnTArg92Trp mutations were detected in another one,
eight, and four probands, respectively, and haplotype
analysis in families carrying these recurring mutations
inferred their origin from three common ancestors. The
milder phenotype of the bMHC mutations may account
for the presence of these founder effects, whereas pop-
ulation dynamics alone may have overridden the repro-
ductive disadvantage incurred by the more lethal, cTnT
Arg92Trp mutation.
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Introduction
Hypertrophic cardiomyopathy (HCM), an autosomal
dominantly inherited primary cardiac disease, histori-
cally has been defined as a rare cardiomyopathy of un-
known cause, characterized by hypertrophy of the ven-
tricular muscle, in the absence of other predisposing
clinical conditions (Teare 1958). Studies initiated during
the past decade have, to some extent, changed this view
of the disease. It is now known that HCM is a disease
of the sarcomere, caused by 100 different mutations
in seven genes encoding proteins constituting the cardiac
contractile unit (reviewed in Bonne et al. 1998). Recent
clinical observational studies performed in the general
population have suggested that, far from being a rare
genetic disorder, the prevalence of HCM is close to 1/
500 individuals (Maron et al. 1995). Furthermore, al-
though genotype-phenotype correlations have empha-
sized the varied clinical spectrum that long has been
associated with this disease, they have also shown that
ventricular hypertrophy is not an inevitable consequence
of the presence of an HCM-causing mutation (Bonne et
al. 1998). However, it appears that mutation carriers do
remain at risk of sudden cardiac death, as adolescents
or young adults, whatever the other clinical manifesta-
tions of their condition (Moolman et al. 1997).
Mutations that are associated with significant mor-
tality, especially at a young age, confer a reproductive
disadvantage. Consequently, within populations, recur-
ring identical disease-causing mutations are more likely
to have arisen independently, rather than to reflect a
common ancestor (de la Chapelle et al. 1993). An in-
vestigation of the origin of eight different HCM-causing
mutations in the b-myosin heavy-chain gene (bMHC)
revealed that they had arisen independently in 12 of
the 14 families studied (Watkins et al. 1993b). This find-
ing led Watkins et al. (1993b) to predict that the prev-
alence of HCM-causing mutations would be comparable
in all populations globally and that founder mutations
would be rare. The continuing identification of diverse
disease-associated mutations in various sarcomeric pro-
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Table 1
HCM-Causing Mutations Present in Two South African
subpopulations
Gene, Mutation,
and Source Ethnic Group Reference
bMHC:
Arg249Gln:a
Ped108 Mixed ancestry Posen et al (1995)
Arg403Trp:b
Ped106 Mixed ancestry Posen et al. (1995)
SB1140 Mixed ancestry Present study
Ala797Thr:
Ped101 White Moolman et al. (1995)
Ped104 Mixed ancestry Present study
Ped110 Mixed ancestry Present study
Ped124 White Present study
Ped131 White Present study
Ped138 White Present study
SB902 White Present study
SB983 Mixed ancestry Present study
SB955 Mixed ancestry Present study
Glu499Lys:
SB1112 White Present study
Arg719Gln:c
SB1159 White Present study
cTnT:
Arg92Trp:
Ped100 Mixed ancestry Moolman et al. (1997)
Ped109 Mixed ancestry Moolman et al. (1997)
Ped137 Mixed ancestry Present study
Ped139 Mixed ancestry Present study
Ped142 Mixed ancestry Present study
SB385 Mixed ancestry Present study
MyBPC:
Arg654His:
Ped136 Mixed ancestry Moolman-Smook et
al. (1998)
Dc756:
SB752 Mixed ancestry Present study
Val896Met:
SB852 White Present study
a Also described, by Watkins et al. (1992), in a Canadian
family.
b Also described, by Dausse et al. (1993), in a French family
and, by Al-Mahdawi et al. (1994), in two Polish families.
c Also described, by Consevage et al. (1994), in a Hispanic
family.
tein–encoding genes in populations in North America,
Europe, Asia, Australia, and South Africa (Bonne et al.
1998, and references therein) supports this reasoning.
Indeed, reports of evidence of founder effects in fa-
milial HCM are rare and often incidental to the main
investigation. The first such report, which appeared in
1993, described two small families of Portuguese descent
harboring the bMHC Gly584Arg mutation (Watkins et
al. 1993b). Five years later, truncating mutations in my-
osin-binding protein C (MyBPC), which were likely to
be identical by descent, were detected in Japanese fam-
ilies, with three kindreds bearing the InsG791 mutation
and two bearing the Int12ASA-2G mutation (Niimura
et al. 1998). In the same year, it was suggested that the
Asp175Asn mutation in the a-tropomyosin gene (aTM),
borne by four Finnish families, might have arisen from
a common ancestor (Ja¨a¨skela¨inen et al. 1998).
We have undertaken investigations of the molecular
spectrum of HCM-causing mutations in the seven im-
plicated genes (reviewed in Bonne et al. 1998) in two
subpopulations living in the Western and Eastern Cape
provinces of South Africa—namely, persons of mixed
ancestry and those of white descent. The history and
population dynamics of these two groups, from the 17th
century to the present, is probably responsible for the
presence of several well-documented founder effects,
particularly in persons of Afrikaans descent (Kotze et al.
1991; Brink et al. 1995; De Jager et al. 1996; Warnich
et al. 1996). The Afrikaners are a subgroup of Afrikaans-
speaking South Africans of northern-European origin,
who have retained a cultural identity largely through
intermarriage and who show minor differences, in al-
lelic-gene frequencies, from the English-speaking white
subpopulation (Botha and Pritchard 1972). The mixed-
ancestry and white subgroups represent an ideal model
with which to investigate whether theHCM-causingmu-
tations that they carry generally arose independently and
fairly recently or whether founder effects are present in
a particular population context. A comparison of the
HCM-associated mutational spectrum of the particular
South African subpopulations studied versus that in
other countries would indicate whether the mutations
either have an independent origin or possibly emanate
from Europe. In the case of identical mutations being
detected in apparently unrelated families, haplotype
analysis would ascertain whether they were of indepen-
dent or founder origin, on the basis of the chromosomal
background in which they are embedded.
Previously, we had reported three bMHC muta-
tions—namely, the novel Ala797Thr (Moolman et al.
1995), the Arg249Gln (Posen et al. 1995), and the
Arg403Trp (Moolman et al. 1993; Posen et al. 1995)
mutations—as well as novel mutations in cTnT
(Arg92Trp [Moolman et al. 1997]) and MyBPC
(Arg645His [Moolman-Smook et al. 1998]).
In the present study, we describe detection of a further
three bMHC mutations, two of which are novel, and
detection of two previously unreported MyBPC muta-
tions and show that the bMHC Arg403Trp mutation
arose independently in South Africa and France. Thus,
it appears that a high proportion of the South African
HCM-causing mutations are unique to South Africa,
confirming the expectation that, in particular subpopula-
tions, HCM is caused by a high proportion of relatively
new mutations. However, both unlike the mutation pro-
file most often seen in other countries and contrary to
generally held views, which have been discussed byWat-
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Figure 1 A, Genetic map of the region flanking the bMHC locus
on chromosome 14q11-12. The order of genetic markers, as well as
the genetic distances between them, used in haplotype construction in
families harboring the bMHC Arg403Trp and the Ala797Thr muta-
tions are shown, according to GeneMap ’99. MYH7 = bMHC;MYH6
= aMHC. B, Genetic map of the region flanking the cTnT locus on
chromosome 1q3. The order of genetic markers, as well as the genetic
distances between them, used in haplotype construction in families
harboring the cTnT Arg92Trp mutation are shown, as mapped by
Watkins et al. (1993a).
kins et al. (1993b), we also report the existence of strong
founder-gene effects in both of the subpopulations stud-
ied. Both the occurrence of founder-gene effects and the
history of the South African subpopulations in which
they were detected are discussed, together with the sig-
nificance that these results have for molecular diagnosis.
Patients and Methods
Patient Study Group and Clinical Examination
The study was performed with the approval of the
University of Stellenbosch ethics committee, with in-
formed consent obtained either from subjects or, in the
case of minors participating in the study, from parents.
A panel of apparently unrelated HCM probands (de-
noted by the prefix “SB”), of mixed ancestry or white
descent, who reside in the Western and Eastern Cape
provinces of South Africa, had previously been estab-
lished, all of whomwere screened for reported and novel
mutations. After identification of a disease-causing mu-
tation in a proband, relatives were traced and pedigrees
were established, whenever feasible. The pedigrees ex-
tended in this manner were given a pedigree number
(denoted by the prefix “Ped”).
As a result of continuing prospective studies, at the
time of the present study the panel consisted of 40HCM-
affected probands, including those 6 in whom an HCM-
causing mutation had been detected in earlier studies;
these were the probands of Ped108 with the Arg249Gln
(Posen at al. 1995), Ped106 with the Arg403Trp (Posen
et al. 1995), and Ped101 with the Ala797Thr (Moolman
et al. 1995) mutations in bMHC, the probands of
Ped100 and Ped109 with the cTnT Arg92Trp mutation
(Moolman et al. 1997), and the proband of Ped136 with
the MyBPC Arg654His mutation (Moolman-Smook et
al. 1998). Mutations detected in the present study, those
previously detected in South African families, relevant
proband or extended-pedigree identification codes, and
either the individual’s or the family’s ethnicity are shown
in table 1.
Clinical examination was performed as described else-
where (Posen et al. 1995). In brief, echocardiographic
diagnosis of HCM was made in the presence of a max-
imal ventricular-wall thickness 13 mm, in the absence
of contributing confounding factors. In children, diag-
nosis of HCM was made with reference to age-adjusted
tables (Feigenbaum 1981, pp. 551–552). Electrocardi-
ographic diagnosis of HCM was based on the presence
of either left-ventricular hypertrophy or abnormal Q
waves. Other echocardiographic or electrocardiographic
changes previously described in familial HCM were
noted for each patient.
Source of DNA and DNA Extraction
Peripheral blood for genotypic analysis was collected
from all probands and family members and from
healthy, unaffected, unrelated control individuals of
mixed ancestry or white descent (100 individuals per
control panel) entered in the study, and DNA was ex-
tracted as described elsewhere (Corfield et al. 1993). Dr.
Lucy Carrier supplied DNA from French family 730
(Dausse et al. 1993).
Mutation Detection
Members of the HCM-affected panel were screened
for previously reported and novel mutations in exons of
bMHC (exons 3–10 and 12–23), MyBPC (exons 8, 18,
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Figure 2 Identification of the Glu499Lys mutation in exon 15
of bMHC. A, Partial sequence of the coding strand of exon 15 of
bMHC in an individual heterozygous for the Glu499Lys mutation,
showing the gra transition, which results in the amino acid substi-
tution of Lys for Glu at codon 499. B, Genotyping the Glu499Lys
mutation by ASREA. Products of MnlI digestion of the 243-bp PCR-
amplified product of exon 15 were separated on a 12%polyacrylamide
gel. Internal MnlI sites generated 87-, 73-, 37-, 16-, and 15-bp frag-
ments in unaffected individuals (lane 2). Loss of one of these sites in
an HCM-affected heterozygous individual resulted in an additional,
undigested 102-bp fragment (lane 1). Lane 3, Lambda PstI molecular-
size marker. The 16- and 15-bp fragments were not resolved on this
gel.
24–28, and 34), cTnT (exons 8, 9, 11, and 14–16), aTM
(exons 2b, 3–5, 6b, 7, 8, and 9ab), cardiac troponin I
(cTnI) (exons 7 and 8), myosin essential light chain
(MELC) (exon 4), and myosin regulatory light chain
(MRLC) (exons 2 and 5) (Vikstrom and Leinwand 1996;
DNA Mutation Database), by PCR-SSCP analysis, and
allele-specific restriction-enzyme analysis (ASREA)when
applicable. Amplified exons in which mobility shifts
were identified by PCR-SSCP analysis were bidirection-
ally sequenced as described elsewhere (Posen et al.
1995).
In the case of the bMHC Glu499Lys mutation,
exon 15 of the gene was PCR-amplified by use of cus-
tom-synthesized primers (DNA Laboratory, Cape
Town)—MYH15F (5′-CACCCACTTTCTGACTGC-
3′) and MYH15R (5′-GAATTCAGGTGGTAAGGCC-
3′)—designed from published gene sequences (Jaenicke
et al. 1990). In the case of variants Dc756 and
Val896Met, exons 24 and 27 (exon numbering is ac-
cording to Niimura et al. 1998), respectively, of
MyBPC were amplified by use of the relevant published
primer sequences (Carrier et al. 1997). PCR amplifi-
cation was performed in a standard reaction mixture
(Moolman et al. 1993), during 30 cycles of the follow-
ing cycling profile: denaturation at 95C (30 s), an-
nealing at either 52C (for Glu499Lys) or 55C (for
Dc756 and Val896Met) (30 s), and extension at 72C
(30 s), by a GeneE thermocycler (Techne). The sequence
changes causing the bMHC Glu499Lys and MyBPC
Val896Met mutations were verified by ASREA. The
bMHC Glu499Lys nucleotide substitution abolished a
MnlI site, whereas the MyBPC Val896Met mutation
created an additional NlaIII site, in the respective PCR-
amplified products. These ASREA tests—or, in the case
of MyBPC Dc756, PCR-SSCP analysis—were used to
genotype 100 unrelated, unaffected control samples of
the relevant ethnic group, for the presence of these
mutations.
Previously reported mutations—namely, bMHC
Arg719Gln (Consevage et al. 1994), additional bMHC
Arg403Trp (Moolman et al. 1993) and Ala797Thr
(Moolman et al. 1995) and cTnT Arg92Trp–mutation
carriers (Moolman et al. 1997)—identified in HCM-af-
fected probands and family members in the present
study, were detected by ASREA, as described elsewhere.
Genotyping Markers at the bMHC and cTnT Loci
Members of Ped106, the French family 730, and in-
dividual SB1140 were genotyped for the bMHC
Arg403Trp mutation, an intragenic marker in the 5′UTR
region of bMHC (MYH7 5′UTR), and with bMHC-
flanking markers at the D14S50, MYH6, and D14S64
loci, covering a distance of8.8 cM (fig. 1A) (GeneMap
’99). In addition to these markers, members of Ped101,
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Figure 3 Identification of the Val896Met mutation in exon 27
of MyBPC. A, Partial sequence of the noncoding strand of exon 27
in an individual heterozygous for the Val896Met mutation, showing
the crt transition (gra, coding strand) that results in the amino acid
substitution of Met for Val at codon 896. B, Genotyping of the
Val896Met mutation, by ASREA. Products of NlaIII digestion of the
310-bp PCR-amplification product of exon 27 were separated on a
12% polyacrylamide gel. An internal NlaIII site generated fragments
of 233 and 77 bp in an unaffected individual (lane 2). The creation
of an NlaIII site in an HCM-affected heterozygous individual resulted
in additional, 141- and 92-bp fragments (lane 1).
Ped104, Ped110, Ped124, Ped131, and Ped138 and in-
dividuals SB902, SB983, and SB995, all carrying the
bMHC Ala797Thr mutation (table 1), were genotyped
at two other loci—D14S283 and D14S264. Members
of Ped100, Ped109, Ped137, Ped139, and Ped142 and
individual SB385, all carrying the cTnT Arg92Trp mu-
tation (table 1), were genotyped with cTnT-flanking
markers at the F13B and D1S53 loci, spanning a dis-
tance of 11.2 cM (Watkins et al. 1993a), and with an
exon 9 cTnT intragenic RFLP marker (TnTex9) (Thier-
felder et al. 1994) (fig. 1B).
The short tandem-repeat markers at the D14S50,
D14S283, MYH7 5′UTR, MYH6, D14S64, D14S264,
F13B, and D1S53 loci were analyzed by PCR-based as-
says, according to standard methods (Brink et al. 1995).
The TnTex9 marker was genotyped by ASREA after
TaqI digestion of the PCR-amplified product of exons 8
and 9, by use of a published primer sequence (Thierfelder
et al. 1994). Forty members of each of the two control
panels were genotyped at each marker locus analyzed in
the family studies, to determine the frequency of alleles
in the two subpopulations.
Haplotype and “Assumed” Haplotype Construction
Most-likely haplotypes were constructed with refer-
ence to gene and marker order on the respective chro-
mosomes, in a family context. In the case of probands
without a traced family, evidence of identity by descent
was accepted if the alleles present allowed construction
of a haplotype (designated as the “assumed haplotype”)
identical with the disease-associated haplotype.
Results
Identification of Novel and Reported Mutations in the
South African HCM-Affected Panel
During screening of the panel of HCM-affected pro-
bands, a novel guanine-to-adenine (gra) transition was
detected in exon 15 of bMHC in one individual (SB1112)
(fig. 2A). This modification results in the substitution of
lysine for the conserved wild-type glutamine at amino
acid residue 499 in the protein (Glu499Lys), fortuitously
resulting in the loss of an MnlI restriction-enzyme site,
allowing mutation screening by ASREA (fig. 2B). Al-
though it was not possible to extend the study to the
proband’s family, the mutation was not present in 100
white control individuals.
A further two, apparently novel mutations were also
detected inMyBPC, one in each of two probands (SB752
and SB852) in the HCM panel. One of these mutations
was a gra transition in MyBPC exon 27 in SB852 (fig.
3A), which would cause the substitution of a methionine
for a valine at residue 896 (Val896Met) and which, since
it created an NlaIII restriction-enzyme site (fig. 3B),
could be detected by ASREA. The second nucleotide
variation, detected in SB752, involves the deletion of a
cytosine at the first base position in codon 796 in
MyBPC exon 24 (Dc756) (fig. 4A); this results in both
a shift in open reading frame 3′ to codon 796 and the
predicted incorporation of 65 aberrant amino acid res-
idues before premature truncation of the protein. This
deletion did not create or abolish a restriction-enzyme
site, and screening for the mutation was subsequently
based on PCR-SSCP analysis (fig. 4B). It was not possible
to perform extended family studies in the case of the
two probands with these sequence variations. However,
the sequence variations were not present in 100 control
individuals of the appropriate subpopulation groups
screened by ASREA or PCR-SSCP analysis.
In addition to the three novel mutations reported
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Figure 4 Identification of the cytosine deletion in codon 796 in
exon 24 of MyBPC. A, Partial sequence of the noncoding strand of
exon 24 of MyBPC in an unaffected individual (i) and a heterozygous
HCM-affected individual (ii), showing the deletion of a g (c, coding
strand) at nucleotide position 2298 (first position of codon 796),which
results in a shift in reading frame. B, PCR-SSCP analysis of amplified
products of exon 24 of MyBPC, separated on a 10% polyacrylamide
gel containing 5% glycerol. The arrows indicate the mobility shifts
caused by the Dc mutation at nucleotide 2298 in a heterozygousHCM-
affected individual (lane 2). The single-stranded conformers of an un-
affected individual are seen in lane 1.
above, three documented bMHC mutations were de-
tected by ASREA in the present study—the Arg403Trp
substitution in an additional proband (SB1140), the
Ala797Thr substitution in eight more probands, and the
Arg719Gln substitution in a single proband of the
HCM-affected panel. The previously reported cTnT
Arg92Trp mutation was detected in a further four
probands.
Thus, if the five mutations previously identified in six
probands are included, a total of nine different muta-
tions have been found in 23 of the individuals consti-
tuting the panel of 40 HCM-affected patients (table 1).
In the remaining 17 probands, none of the 100 pre-
viously reported mutations were present (Bonne et al.
1998), nor were any novel mutations detected in the
screening of selected exons of the seven candidate sar-
comeric protein–encoding genes. Of these genetically un-
diagnosed individuals, 60% were white and the remain-
der were of mixed ancestry.
Origins of the bMHC Arg403Trp Mutation
The bMHC Arg403Trp mutation (Dausse et al. 1993;
Posen et al. 1995) was embedded in two distinct hap-
lotypes in South African Ped106 and French family 730,
indicating their independent origins (fig. 5). However,
individual SB1140 shared alleles—and, therefore, an as-
sumed disease-associated haplotype—with Ped106, im-
plying the existence of a common ancestor (fig. 5). The
validity of this assumption was supported by the fact
that the allele occurring at each of the markers from
which the disease-associated haplotype was constructed
was not the one carried most commonly in the control
mixed-ancestry population (fig. 6, legend). The disease-
associated haplotype extended from D14S50 to
D14S64, a distance of 8.8 cM, with no evidence of
recombination in the extended Ped106 (data not shown).
Origin of the bMHC Ala797Thr Mutation
In the six pedigrees—Ped101, Ped104, Ped110,
Ped124, Ped131, and Ped138—that harbored bMHC
Ala797Thr, a common core haplotype encompassing the
bMHC and aMHC loci segregated with the disease-caus-
ing mutation, suggesting descent from a shared ancestor
(fig. 6). Furthermore, the two parents shown in the
Ped101 subset (fig. 6) both carried the Ala797Thr mu-
tation, embedded in the disease-associated haplotype,
suggesting that they may be related. Within the families,
the shared haplotype generally extended8.8 cM across
the region flanking bMHC and aMHC, with evidence
of recombination both between MYH7 5′UTR and the
proximal D14S283 marker, in Ped138, and between
MYH6 and the distal D14S64 marker, in Ped104 (fig.
6). These events reduced the extent of the conserved
haplotype to 8.8 cM, which, because of both the un-
availability of mapped markers between MYH6 and
D14S64 and the small genetic distance between MYH7
and D14S283 (fig. 1A), could not be substantially nar-
rowed further. The alleles at the marker loci genotyped
in individuals SB902, SB983, and SB995 were also com-
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Figure 5 Haplotypes across the b and aMHC loci associated with the bMHC Arg403Trp mutation. The disease-associated haplotypes
in a representative subset of South African Ped106 and the French family 730, as well as the assumed haplotype of individual SB1140, bearing
the bMHC Arg403Trp mutation are boxed. In the married-in individuals, the haplotypes were inferred on the basis of those of their children.
The marker loci used in haplotype construction, covering a distance 8.8 cM, are indicated to the left of the subsets, in centromeric-telomeric
order, from top to bottom. The frequencies of the alleles of the markers genotyped in the control mixed-ancestry subpopulation are given in
the legend to figure 6. Note that in the Ped106 subset shown there were no clinically HCM-affected mutation carriers; however, in the extended
pedigree there were numerous affected individuals (Posen et al. 1995). MYH7 = bMHC; MYH6 = aMHC; R = arginine; W = tryptophan.
patible with that of the common extended ancestral dis-
ease-associated haplotype that was8.8 cM (fig. 6). The
existence of a common ancestor was supported by the
fact that the allele at the markers fromwhich the disease-
associated haplotype was formed was generally not the
one carried most commonly in either of the control sub-
population groups (fig. 6, legend). The only exception
was at the D14S50 locus in an individual in Ped101, in
whom a recombination event had occurred. Five of the
families or probands carrying the bMHC Ala797Thr
mutation were members of the white subpopulation, and
four were of mixed ancestry (table 1).
Origin of the cTnT Arg92Trp Mutation
In the five families that carried the cTnT Arg92Trp
mutation and that could be traced (i.e., Ped100, Ped109,
Ped137, Ped139, and Ped142), a common disease-as-
sociated haplotype, stretching, without recombination,
between marker loci D1S53 and F13B (a distance of
∼11.2 cM) in the extended pedigrees, segregated with
the mutation (fig. 7). Since genotyping was not contin-
ued beyond these markers, the size of the conserved frag-
ment is unknown and may indeed extend further. In
addition, individual SB385 possessed, at the markers
genotyped, alleles that were compatible with the disease-
associated haplotype. The data suggest that, in these
families and this individual, all of which are members
of the mixed-ancestry subpopulation, the mutation is
identical by descent. The validity of this assumption was
supported by the fact that the allele occurring at each
of the markers from which the disease-associated hap-
lotype was constructed was not the one carried most
commonly in the control mixed-ancestry population, ex-
cept at the biallelic TnTex9 marker (fig. 7, legend).
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Discussion
The Spectrum and Possible Effects of HCM-Causing
Mutations in South Africa
Our investigations into the molecular causes of HCM
in a panel of 40 apparently unrelated South African pa-
tients revealed that previously reported mutations, oc-
curring worldwide, were apparently rare in this country.
Of these mutations, only the bMHC Arg719Gln (Con-
sevage et al. 1994) and Arg249Gln (Watkins et al. 1992;
Posen et al. 1995) substitutions were detected in two
separate probands of the South African HCM panel.
Additionally, the bMHC Arg403Trp mutation, which
originally had been described as occurring in South Af-
rica (Moolman et al. 1993), subsequently was reported
in French and Polish families (Dausse et al. 1993; Al-
Mahdawi et al. 1994). Other than the aforementioned
bMHC mutations, none of the 100 other mutations
detected globally (Bonne et al. 1998, FHC database) in
bMHC, cTnT, MyBPC, aTM, MELC, MRLC, or cTnI
were present in the South African subpopulations
screened. The acardiac actin gene, which recently had
been implicated as another cause of HCM (Mogen-
sen et al. 1999), was not screened in the present
investigation.
We previously had described three novel mutations
in the South African population—namely, bMHC
(Ala797Thr) (Moolman et al. 1995), cTnT (Arg92Trp)
(Moolman et al. 1997), and MyBPC (Arg654His)
(Moolman-Smook et al. 1998). Here, we have presented
evidence of three additional novel disease-causing mu-
tations identified in HCM-affected individuals in the
Western and Eastern Cape provinces of South Africa,
one in bMHC and two in MyBPC.
The bMHC Glu499Lys substitution occurred at a res-
idue conserved in myosin proteins, across a range of
species—including human, rabbit, mouse, pig, hamster,
and rat—and in a region that probably forms an inter-
face with the reactive sulfydryls (Rayment et al. 1995).
The Dc756 MyBPC deletion, which occurs in a region
encoding the Ig-like module-C5 domain of the protein,
results in a reading frameshift, with predictedproduction
of an aberrant and prematurely terminated molecule.
The resultant loss of the carboxy-terminal residues of
MyBPC is likely to affect the ability of the protein both
to be incorporated into the A-band of the sarcomere and
to bind to myosin and titin (Freiburg and Gautel 1996).
Considering the Val896Met substitution, structurally
similar nonpolar amino acid residues with aliphatic hy-
drocarbon side chains occur at position 896 in MyBPC,
across isoforms. Valine, which has a branched side chain,
occurs in human cardiac MyBPC at residue 896 and
differs, by a single methyl group, from the isoleucine
residue found in human fast and slow, chicken cardiac,
and rat MyBPC isoforms at this position. It can be sur-
mised that replacement of this valine by methionine,
with its longer, unbranched side chain containing a sulfur
group, will affect the conserved fibronectin type 3 struc-
ture of MyBPC module C7 (Gautel et al. 1995). The
latter domain, along with modules C8–C10, is necessary
for incorporation of the protein into the A-band of the
sarcomere (Freiburg and Gautel 1996).
It was not possible to follow the segregation of either
these described variants or the disease, in the families of
the three probands. However, their occurrence in con-
served positions and/or regions postulated to be func-
tionally important protein domains of bMHC and
MyBPC, as well as their absence in control panels of
both subpopulation groups studied, implicates them as
disease-causing mutations.
Independent Origin of the South African Mutations
In the 17th century, French Huguenots settled in the
Western Cape region of South Africa (Botha and Beigh-
ton 1983), so the possibility existed that the bMHC
Arg403Trp mutation in Ped106 and French family 730
were identical by descent. The mild phenotypic expres-
sion associated with this mutation on both continents
(Dausse et al. 1993; Posen et al. 1995) also suggests that
it might have spread by migration, since reproductive
fitness might be unaffected in families harboring it.How-
ever, a comparison of the haplotypes associated with the
mutation in these two kindreds provides evidence in fa-
vor of their independent origin (fig. 5). The bMHC
Arg403Trp mutation has also been reported in Polish
families (Al-Mahdawi et al. 1994), and the bMHC
Arg249Gln and Arg719Gln mutations identified in the
South African HCM-affected panel also occur in Ca-
nadian and Hispanic families, respectively (Watkins et
al. 1992; Consevage et al. 1994). We do not know
whether the South African versions of these mutations
are identical by state or identical by descent, to their
counterparts in the other populations. It is possible that
French immigrants to Canada and South Africa may
share common ancestry for the Arg249Gln mutation.
However, since immigrants from Poland and Spain have
not made a major contribution to the South African gene
pool, it is likely that Arg403Trp and Arg719Gln are
identical by state, rather than identical by descent, to
those in these two countries.
Six of the nine HCM-causing mutations detected in
South Africa are novel and, when the bMHCArg403Trp
data presented here also are considered, at least one of
the other three also has an independent origin, whereas
the source of the other two mutations could not be in-
vestigated. No other of the disease-associated mutations
reported worldwide occurs in the South African groups
studied. These data support the proposal that the profile
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of HCM-causing mutations will be unique in different
geographic areas and that it is the result of numerous
nascent mutations.
Founder Effects in South African HCM-Affected
Families
In addition to the evidence supporting the independent
occurrence of several HCM-causing mutations in pro-
bands originating from the Western and Eastern Cape
provinces, three of the mutations were found in more
than one apparently unrelated affected individual. The
bMHC Arg403Trp and Ala797Thr mutations were
found in two and nine probands, respectively, and the
cTnT Arg92Trp mutation was found in six apparently
unrelated affected individuals. Haplotype analysis across
the bMHC and cTnT loci in relevant families and in-
dividuals (table 1) revealed that all the individuals who
carried the same mutation also shared either a disease-
associated haplotype or a haplotype that was assumed
to be disease associated (figs. 5–7). The haplotype was
conserved over a region of 8.8 cM of the bMHC locus
in persons harboring the Ala797Thr mutation and over
a region of 11.2 cM of the cTnT locus in individuals
carrying Arg92Trp. These data are consistent with the
possibility that each of the three recurring mutations is
identical by descent—because of the existence, in each
case, of a common ancestor—rather than being identical
by state.
This report is the first that substantiates the existence
of strong founder effects as the cause of HCM in gen-
erally homogeneous population groups. Ja¨a¨skela¨inen et
al. (1998) have suggested that the occurrence of theaTM
Asp175Asn mutation in four unrelated Finnish kindreds
might reflect the presence of a common ancestor. This
finding would not be unexpected, since the genetically
homogeneous population of Finland is known for its
“Finnish disease heritage” (de la Chapelle 1993, p. 857).
However, the proposal was based only on the fact that
all the HCM-affected relatives shared the same allele at
an aTM intragenic marker, and the frequency of this
allele in this homogeneous population was not given. In
the two Cape subpopulations studied, the likely exis-
tence of two founder individuals for the bMHC
Ala797Thr and cTnT Arg92Trp mutations was based
on extended haplotype data.
The presently reported exception to the general find-
ing of the independent nature of HCM-causing muta-
tions is not unanticipated. Founder-gene effects are not
uncommon in South Africa, especially among the Afri-
kaner subgroup of the white population (Botha and
Beighton 1983; Kotze et al. 1991; Brink et al. 1995; De
Jager et al. 1996; Warnich et al. 1996). These effects are
probably due to bottlenecks in gene transmission, caused
by rapid expansion of the white population in the West-
ern Cape after the initial European colonization (Botha
and Beighton 1983). During the period 1691–1791, the
colony’s population increased from 1,000 to 13,028 (Bo-
tha and Beighton 1983), mainly because of natural ex-
pansion, since only 766 new European immigrant sur-
names were tabulated during this period (Theal 1922;
Cameron and Spies 1992, pp. 11–139). At the same
time, a group of ethnic admixture originated by inter-
mingling of the European immigrants, mostly with the
resident Khoi-khoi and San peoples (the Khoisan) but
also with native black Africans and, later, with slaves
transported from Malaysia and other East Indian coun-
tries (Cameron and Spies 1992, pp. 11–139). This group
has become a distinct genetic entity, herein referred to
as “mixed ancestry” (often referred to as “colored”),
which has largely been maintained by intercultural mat-
ings (Botha and Pritchard 1972;May andDu Toit 1989).
The history of the white and mixed-ancestry subpopula-
tions of the Western Cape also explains the presence of
the bMHCAla797Thr mutation in both subpopulations.
After the initial colonization of theWesternCape, chang-
ing economic circumstances resulted in the migration of
individuals to the Eastern Cape (Botha and Beighton
1983).
The ethnicity of the three ancestors in whom the foun-
der mutations arose cannot be ascertained; however,
since our data suggest that it is unlikely that the mu-
tations originated in Europe, it can be assumed that they
arose in Africa. Since HCM-causing mutation screening
has not been performed in the Khoisan or black African
subpopulations, the latters’ contribution to the pool of
disease-associated alleles cannot be established. It is pos-
sible that the bMHC Ala797Thr mutation arose in the
white population, postcolonization, and thereafter was
introduced into the mixed-ancestry group. However,
both the mild phenotype generally accompanying this
mutation (authors’ unpublished observations) and the
disease-associated haplotype of 8.8 cM, allow specu-
lation that this is an older mutation, which arose in the
indigenous Khoisan people, whose presence in the West-
ern Cape predated migration of black Africans from
north of the Cape Province (Cameron and Spies 1992,
pp. 11–139). Its presence in families of white descent
would reflect the blurring of ethnic distinctions, because
of earlier admixture among the subpopulations living in
the Western Cape. In contrast, the reduced life expec-
tancy previously reported to be associated with the cTnT
Arg92Trp mutation (Moolman et al. 1997), together
with the extensive conserved haplotype in which it is
embedded in so many families, suggests a recent mu-
tational event. Since this variant has been detected only
in persons of mixed ancestry, it can be speculated that
it arose in an ancestor of this subgroup and then, despite
its malignant phenotype, increased in frequency during
a time of rapid population expansion. The decreased
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survival associated with this cTnT mutation was most
pronounced in male family members (Moolman et al.
1997). Therefore, it is possible that inheritance of the
mutant allele was either through female carriers in the
generally large families seen to this day in this subpopu-
lation group or through those male carriers who did
survive to reproductive age. Rationally, pronounced
founder effects are not expected to be associated with
mutations resulting in significant mortality during re-
productive years (de la Chapelle 1993; Watkins et al.
1993b). We propose that the population dynamics seen
in the South African subpopulations studied here have
overridden the reproductive disadvantage conferred by
these mutations.
The prevalence of founder effects in a population may
have an impact on the success of anymolecular diagnosis
program. In the Western and Eastern Cape provinces,
the bMHC Ala797Thr mutation alone accounts for
∼25% of the HCM cases in the panel, whereas the
cTnT Arg92Trp is the causative mutation in 15%, and
the bMHC Arg403Trp in 5%, of affected individuals.
Three other bMHC mutations—namely, Arg249Gln,
Arg719Gln, and Glu499Lys—collectively account for
another 7.5% of disease cases. Therefore, in the South
African subpopulations studied here, five bMHC mu-
tations are collectively responsible for ∼37.5% of HCM.
This finding is very different from the profiles seen in
most North American and European referral centers,
where numerous “private” bMHC mutations are re-
ported to account for ∼30%–40% of HCM. Conse-
quently, we have adopted a mutation-screening pro-
gram in which any patient referred for molecular di-
agnosis is first screened for these three founder muta-
tions, by ASREA, and more extensive mutation screen-
ing is performed only in their absence. Such a focused
molecular diagnosis program saves both time and
money.
Moreover, the presence of large cohorts of affected
individuals who are members of relatively homogeneous
subpopulations bearing the same bMHC Ala797Thr or
cTnT Arg92Trp mutations will make it possible to de-
velop a clearer picture of the true genotype-phenotype
correlations. This is especially relevant, since it is in-
creasingly being realized that the clinical expression of
a disease is context dependent and is influenced not only
by the presence of a recognized major-locus mutation
but also by the genetic and environmental background
in which it occurs (Bonne et al. 1998). In a previous
study based on two families (Ped100 and Ped109), the
cTnT Arg92Trp mutation was shown to be associated
with only moderate hypertrophy but with a high risk of
sudden cardiac death (Moolman et al. 1997). A similar
clinical picture was evident in the additional families
bearing this mutation (our unpublished observations).
However, although the initial report of the bMHC
Ala797Thr mutation seen in one nuclear family sug-
gested a poor prognosis (Moolman et al. 1995), contin-
uing investigations have suggested a milder clinical dis-
ease course (authors’ unpublished observations). It is
anticipated that further extensive genotype-phenotype
correlations will facilitate more-accurate prognostica-
tion and thereby improve patient management and coun-
seling of this clinically insidious condition.
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